UT receptor peptide antagonist-UFP 803

2018-09-21

Introduction 

UFP-803 (H-Asp-c[Pen-Phe-DTrp-Dab-Tyr-Cys]-Val-OH), [Pen 5, DTrp 7, Dab 8] U-II (4-11), is a peptidic UT (urotensin-II receptor) receptor ligand. It is generated from a potent UT receptor antagonist, urantide ([Pen 5, DTrp 7, Orn 8] U-II (4-11), which has the agonist activity at human recombinant UT receptors in a Ca 2+ mobilization assay. The experiments by Guerrini et al. showed that the substitution of Orn 8 with diaminobutyric acid in [Dab 8] U-II leads to a reduction in potency, but also attenuates the efficacy of the peptide, so this chemical modification has been applied to the urantide sequence to generate the peptide UFP-803.

Biological Activity

As a derivative of Urotensin-II (U-II), UFP-803 has a biological effect of antagonizing U-II in a dose-dependent manner. In animal experiments, 10nmol/kg of UFP-803 completely inhibited U-II-induced vasoconstriction, but its efficacy was lower than that of urantide, and it was found to have a weak effect of promoting intracellular Ca 2+ transfer in hamster ovary cells. Using RNA interference-silenced UT mRNA expression, UFP-803 and urantide have a good correlation with UT antagonism. In the study of the nervous system, UFP-803 can reverse U-II to promote the release of norepinephrine from cerebral cortical cells and inhibits U II to maintain arousal.

Function

The UT receptor system is implicated in the pathogenesis of a number of cardiovascular, renal and metabolic disorders, and Urotensin-II's action can be mediated by UT receptors. UT receptor is expressed in a variety of peripheral organs, such as kidney, liver, endocrine glands, and especially cardiocascular tissues. In vitro and in vivo assays, UFP-803 is a potent and selective UT receptor ligand. Although this peptide exhibits a certain receptor agonist activity, it exhibits its antagonistic activity to the greatest extent in these experiments. Moreover, UFP 803 can be a chemical template for identifying novel UT receptor ligands, as well as a pharmacological tool for in vitro and studying the role played by the U-II/UT receptor system in physiology and pathology in vivo.

References

1. Camarda, V., Spagnol, M., Song, W., Vergura, R., Roth, A. L., Thompson, J. P., ... & Cavanni, P. (2006). In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5, DTrp7, Dab8] urotensin II (4–11) (UFP‐803). British journal of pharmacology, 147 (1), 92-100.

2. Leprince, J., Chatenet, D., Dubessy, C., Fournier, A., Pfeiffer, B., Scalbert, E., ... & Guilhaudis, L. (2008). Structure–activity relationships of urotensin II and URP. Peptides, 29 (5), 658-673.

3. Merlino, F., Di Maro, S., Munaim Yousif, A., Caraglia, M., & Grieco, P. (2013). Urotensin-II ligands: an overview from peptide to nonpeptide structures. Journal of amino acids, 2013.

Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!

 Urantide is a UⅡ receptor antagonist. It can effectively alleviate monocrotaline (MCT)-induced PAH in a rat mode ...

 Acetyl pepstatin, nature products of yeast fermentation, is general inhibitors of the family of aspartic proteas ...

  Margatoxin (MgTX) is a 39 amino acid peptide with significant sequence homology to charybdotoxin (ChTX), and ha ...

Background Aclerastide, one angiotensin receptor agonist, is the active ingredient of DSC127 and its general structure is sho ...

Proteolytic Processing of APP Following discovery of the full-length APP cDNA clone, numerous studies were undertaken to dete ...

Contact Us

USA

Address:

Tel: |

Email:

Germany

Address:

Copyright © 2024 Creative Peptides. All rights reserved.